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Abstract
Two different techniques are developed for the determination of clopidogrel in pharmaceutical preparations. HPLC method
has been developed where chromatographic analysis is performed on Nova-Pak® C18 column (3.9 mm × 150 mm, 5 µm) with an
ammonium formate buffer adjusted with formic acid to pH 4.0, acetonitrile (40:60, v/v) as mobile phase, and detection at 225 nm.
Good linearity (0.9993, r), accuracy (≥ 99.20 %), and precision (≤ 0.6 RSD) were obtained. Potentiometric measurments are based
on tetrakis (p-chlorophenyl) borate-clopidogrel ion-pair as an electroactive material incorporating a plasticized PVC membrane with
o-nitrophenyl octyl ether or dioctyl phthalate. The sensor is conditioned for at least two days in 0.1 M drug solution before use. It
exhibits fast and stable Nernstian response for clopidogrel over the concentration range of 1.0 × 10 -5 ~ 1.0 × 10 -2 M and pH range of
1.5 - 4.0. Results with an average recovery of 100.6% and a mean standard deviation of 0.86% of the nominal were obtained. The
sensor shows reasonable selectivity towards clopidogrel hydrogen sulphate in presence of many cations. No significant interferences
are caused by drug excipients and diluents.
Key words: HPLC, potentiometry, pharmaceutical analysis, clopidogrel determination

Introduction
Clopidogrel hydrogen sulphate (CG-H 2SO 4),
methyl(+)-(S)-(o-chlorophenyl)-6,7
dihydrothien[3,2c]pyridine-5(4H)-acetate hydrogen sulphate (Scheme 1) is
a new thienopyridine derivative. Clopidogrel is similar to
ticlopidine in chemical structure but different in the side
effect of reduction of white cells. Clopidogrel is indicated for the reduction of atherosclerotic events (myocardial infraction, stroke, and vascular death) in patients
with atherosclerosis documented by recent stroke, recent
myocardial infraction, or established peripheral arterial disease. Active metabolite of clopidogrel selectively
inhibits adenylate cyclase, ADP-induced platelet aggregation by direct inhibition of ADP binding to its receptor,
which further leads to the inhibition of subsequent ADPmediated activation of the GPIIb-IIa complex(1).
Clopidogrel is inactive in vitro, and hepatic biotransformation via cytochrome P450 pathway, primarily by
CYP3A4 and CYP3A5(2), is essential for its in vivo antiplatelet activity. The active metabolite(3), a thiol compound,
is formed by the oxidation of clopidogrel to 2-oxoclopidogrel and subsequent hydrolysis. The active metabolite
* Author for correspondence. Tel: +20121530134;
E-mail: amrlotfy2000@yahoo.com

is highly labile and remains undetected in plasma. It was
isolated in vitro from rat microsomes and the structure
elucidation(3) was performed on a stabilized acrylonitrile
derivative. Following an oral administration in humans,
plasma levels of clopidogrel are very low due to extensive
metabolism and difficulties of quantification. The metabolite (the carboxylic acid derivative) is pharmacologically
inactive and represents 85% of circulating metabolites in
human plasma. Since neither the parent drug nor the active
metabolite is detected in plasma, measurement of pharmacodynamic effect by estimating platelet aggregation(4) is
believed to be a better measure for in vivo estimations. The
major circulating compound is the inactive carboxylic acid
derivative, which is formed by hydrolysis of the ester function by carboxyl esterase(5). Few methods for the determination of clopidogrel have been reported in literature.
Recently, the nonenzymatic and enzymatic chiral inversion of clopidogrel has been investigated in vitro using 1HNMR and a chiral HPLC procedure(6). Moreover, a nonstereospecific HPLC assay method was also used to monitor
the hydrolysis of clopidogrel.
Possible in vivo chiral inversion of carboxylic acid
metabolite of clopidogrel in rats was also studied using
(S)-(1-naphthyl)ethyl amine as a derivatisation reagent
and a HPLC method with spectrofluorimetric detec-
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tion(6). Reversed phase HPLC methods for the determination of clopidogrel in pharmaceutical preparations
have also been reported (7,8). For the determination of
carboxylic acid metabolite of clopidogrel in plasma and
serum, a GC-MS(9) and LC-ESI-MS(10) methods have
also been reported. GC method was used for determination of clopidogrel in tablets (11). Estimation of carboxylic acid metabolite of clopidogrel in wistar rat plasma by
HPLC and its application to a previous pharmacokinetic
study(12). Stability indicating HPTLC determination of
clopidogrel hydrogen sulphate as bulk drug and in pharmaceutical dosage form has also been reported (13). Focus
of the present study was to develop an accurate, precise
and robust liquid chromatographic method for the determination of clopidogrel hydrogen sulphate in tablets. The
proposed method was validated according to the International Conference on Harmonization (ICH) guidelines (14).
No sensor or potentiometric method for determination of
clopidogrel has been reported in the literature to date.
This study also includes development of a new potentiometric sensor based on tetrakis (p-chlorophenyl) borateclopidogrel ion pair as a novel electroactive material
incorporating in poly(vinylchloride) matrix membrane
plasticized with either o-nitrophenyl octyl ether or dioctyl phthalate for determination of clopidogrel.

MATERIALS AND METHODS
I. Materials

(I) Instrumentation
The LC system consisted of a Waters model 481 UV
detector, a Shimadzu LC-6A pump, and a model 7125
injector (Rheodyne, Berkeley California, USA) with
20 µL sample loop. The output signals were monitored
and integrated using Perkin-Elmer TotalChrom software
(version 6.2.1.).
(II) Chromatographic Conditions
The elution was isocratic. The mobile phase consisted of a mixture of aqueous 0.05 M ammonium formate
adjusted with formic acid to pH 4.0 and acetonitrile (40:60,
v/v). Ammonium formate buffer pH 4.0 (0.05 M) was
prepared as follows(15): 3.15 g of ammonium formate was
dissolved in 950 mL of water, pH was adjusted to value 4.0
± 0.1 with formic acid (diluted with water in ratio 1:5), and
buffer was diluted to 1000 mL with water and then was
filtered through a 0.45-µm (HVLP, Germany) membrane
filter. The mobile phase also was filtered through a 0.45µm (HVLP) filter prior to use. A symmetry C18 analytical
column (3.9 mm × 150 mm, 5 µm particle size) (Waters,
USA) was used for determination of the drug under investigation. The flow rate of mobile phase was 1.0 mL min1 and the column was operated at ambient temperature
(~25°C). Sample injection volume was 20 µL and UV
detector was set at a wavelength of 225 nm.
(III) Preparation of Stock and Working Standard Solutions
The stock solution of CG-H 2SO4 (500 µg mL -1) was
prepared by dissolving 0.05 g of CG-H 2SO4 (99.78 %) in
methanol in a 100-mL volumetric flask. Six different working/calibration solutions in mobile phase were prepared by
appropriate dilution of the stock solution. The concentration range of the working standard solutions was 1.0-30.0
µg mL -1 as shown in the calibration curve (Figure 1).
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(CG-H 2SO 4) was received from Pharma Company, 6
October City, Cairo, Egypt. HPLC grade acetonitrile was
obtained from SDS (de Valdonne, France). Analytical
grade ammonium formate was purchased from SigmaAldrich, Germany. Formic acid was obtained from
E. Merck (Darmstadt, Germany). Plavix tablets were
purchased from the market. Each plavix tablet consists of
75 mg of (CG-H 2SO 4). Grade 1 water was obtained from
a Milli-Q ultrapure water purification system (Millipore,
Bedford, MA, USA). Tetrakis (p-chlorophenyl) borate
(TpClPB) and tetrahydrofuran (THF) were obtained from
Aldrich Chemical Co. (Milwaukee, USA). PVC (Breon
S 110/0P) was obtained from BP Chemicals International (Barry, UK), o-nitrophenyl octyl ether (o-NPOE) was
purchased from Fluka (Buchs, Switzerland) and dioctyl
phthalate (DOP) from BDH (Poole, England).

II. High Performance LC Method
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Scheme 1. Chemical structure of clopidogrel hydrogen sulphate.
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Figure 1. The calibration curve for clopidogrel hydrogen sulfate.
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(IV) Sample Preparation
Ten tablets were weighed and finely powdered. A
quantity of powder equivalent to one tablet (255.1 mg)
containing 75 mg of (CG-H 2SO 4) was transferred in a
100-mL volumetric flask, dissolved in methanol, and
filtered through 0.45-µm (HVLP, Germany) membrane
filter. The filtrate (100, 200, 400 µL) was quantitatively
transferred to three different 10-mL volumetric flasks
to give three different concentrations (7.5, 15 and 30 µg
mL -1) respectively, and the solutions were diluted to the
volume with mobile phase. A typical chromatogram of
(CG-H 2SO 4) is shown in (Figure 2).
III. Potentiometric Method
(I) Instrumentation
Electrochemical measurements were made at room
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temperature (25 ± 1°C) with a PTI-15 digital pH meter
using TpClPB-clopidogrel membrane sensor in conjunction with an EIL type RJ 23 calomel reference electrode.
A glass Ag-AgCl combination electrode (consort, S 210
B BB5) was used for pH measurements. The ISE internal reference solution was a silver-silver chloride in 0.1
M clopidogrel solution.
(II) Clopidogrel PVC Membrane Sensor
Clopidogrel sensor was assembled as described
previously(16,17). TpClPB (40 mg), o-nitrophenyl octyl
ether or dioctyl phthalate (360 mg) and PVC (170 mg)
were used. The sensor was conditioned by soaking in 0.1
M clopidogrel solution for at least two days before use
and was stored in the same solution when not in use.
(III) Sensor Calibration
The sensor was calibrated by spiking with successive
aliquots of standard solution into a 10 -5 M solution of the
calibrant. Alternatively, the calibration was carried out
by immersing the sensor into a 50-mL beakers containing 20 mL of aliquots of standard 1.0 × 10 -5 - 1.0 × 10 -2 M
clopidogrel solution starting from low to high concentrations. The electromotive force (e.m.f.) was plotted as
a function of the logarithm of the clopidogrel concentration. The calibration graph was used for subsequent
determination of unknown concentration of clopidogrel.
(IV) Selectivity Coefficient
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Potentiometric selectivity coefficients KCG.,B were
evaluated using the separate solution method according
to the equation:
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(V) Determination of Clopidogrel in Pharmaceutical Preparation
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where ECG. and EB are the response potentials of
the sensor for clopidogrel ion and interferent B at 10 -2 M
respectively. S is the sensor slope (mV decade -1).
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Figure 2. A typical chromatogram of clopidogrel at different
concentrations.

Ten tablets were weighed and the average weight was
calculated. The tablets were crushed to furnish a homogeneous powder and a quantity equivalent one tablet
(0.2551 g) which contains 75 mg of (CG-H 2SO 4) was
weighed in a 50-mL volumetric flask, dissolved in methanol, and filtered. The filtrate (4.1 mL) corresponding to
21 mg CG-H 2SO 4 was quantitatively transferred to a 50mL volumetric flask and diluted to the mark with doubly
distilled deionized water. After the pH was adjusted to
3.0, potential of the sensor was measured and compared
with the calibration curve.
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Results and discussion

The limit of detection (LOD) was calculated according to Reference 15.

I. HPLC Method

LOD =

(I) Method Development
1. Choice of Stationary Phase
Chromatographic method was used on two batches
of C18 columns provided by Waters (3.9 mm × 150 mm,
5 µm) and another manufacture to check the column
performance. Due to difference in peak shape and in the
retention time, the waters column gave the best results.
2. Choice of Mobile Phase
(CG-H 2SO 4) was eluted before 5 min with a mobile
phase composed of an ammonium formate buffer pH 4.0
and acetonitrile (40:60, v/v) but by using a mobile phase
composed of ammonium formate and acetonitrile (55:45,
v/v) adjusted at the same pH value, (CG-H 2SO 4) was
eluted at about 9 min. However, at the same composition
and different pH, no significant difference in retention
time was observed. Hence a mobile phase consisting of
ammonium formate and acetonitrile (40:60, v/v) adjusted
at pH 4.0 was chosen.
(II) Method Validation
Only (CG-H 2SO 4) was observed by analyzing the
tablet solution samples, showing that the method was
selective.
1. Limits of Detection and Quantitation
The limit of quantitation (LOQ) was established at a
signal-to-noise ratio of 10. The LOQ of (CG-H 2SO 4) was
determined by six injections of drug at the LOQ concentration and was found to be 1.0 µg mL -1 corresponding to
0.0034 mg of tablet.

3.3. σ
S

where σ is noise peak-to-peak of baseline in the chromatogram of placebo solution, S is slope of the regression
line acquired by measuring of the linearity. The limit of
detection (LOD) of (CG-H 2SO4) was 0.3 µg mL -1.
2. Linearity
Linearity was evaluated by analysis of working standard solutions of (CG-H 2SO 4) at six different concentrations (14). Signals and concentrations of the drug were
subjected to regression analysis to calculate the calibration equation and correlation coefficients. The regression
equation obtained for the pharmaceutical preparations
was y = 0.267x + 0.07 (r = 0.9993, n = 6). The range of
linearity was 1.0 – 30.0 µg mL -1.
3. Accuracy
Accuracy of the method was determined by analyzing the solution which equivalent to one tablet. Three
solutions of concentration levels at 7.5, 15 and 30 µg mL -1
were made in triplicate from this sample and analyzed for
3 consecutive days. Solutions for the calibration curves
were prepared fresh every day. The assay accuracy variation shown in terms of relative mean error (RME) and %
recovery are tabulated in Table 1(14). The RME values are
below ± 1.0% for the intra-day assay experiments. Due
to the good accuracy, no internal standard was needed.
4. Precision
Precision of the method for the determination of
(CG-H 2SO 4) was studied using the parameters repeatability, intermediate precision, and robustness.

Table 1. Accuracy of determination of (CG-H2SO4) in tablets using HPLC
Day of analysis

Theoretical concentrations
(µg mL-1)

Day 1

7.5

Day 2

Day 3

Actual concentrations
(µg mL-1) (n = 3)

Recovery (%)

RME (%)

7.45

99.40

-0.67

15

14.98

99.88

-0.13

30

29.85

99.50

-0.50

7.44

99.20

-0.80

15

14.92

99.46

-0.53

30

29.89

99.63

-0.37

7.44

99.20

-0.80

15

14.90

99.33

-0.67

30

29.89

99.63

-0.37

7.5

7.5
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Table 2. Inter- and Intra-day assay variation of (CG-H2SO4) using HPLC method. The inter-day data were obtained by randomly choosing
one replicate for each day
Day of analysis

Theoretical concentrations
(µg mL-1)

Actual concentrations
(µg mL-1) (n = 3)

SD

RSD (%)

7.5

7.45

0.04

0.47

15

14.98

0.01

0.09

Intra-day:
Day 1

Day 2

Day 3

Inter-day:

30

29.85

0.11

0.36

7.5

7.44

0.04

0.57

15

14.92

0.06

0.38

30

29.89

0.08

0.26

7.5

7.44

0.04

0.57

15

14.90

0.07

0.48

30

29.89

0.08

0.26

7.5

7.46

0.03

0.38

15

14.96

0.03

0.19

30

29.92

0.06

0.19

Repeatability in the intra-day variations in assay
obtained at different concentration levels is expressed in
terms of RSD values calculated from the data of each day
for 3 days. RSD values of assay were found to be below
0.5% (Table 2).
Intermediate precision, which is the inter-day variation at the same concentration level, was determined on
successive days. The intermediate precision for assay of
(CG-H 2SO 4) was found to be below 1.0% RSD (Table 2.).
Robustness of a method is a measure of its capacity to
remain unaffected by small variations in method conditions. The robustness of the proposed method was evaluated by altering pH of the mobile phase. The results (not
shown) indicated lack of significant differences between
the conditions of the method developed. The method is
satisfactory for determination of (CG-H 2SO 4) in tablets.
These results also show that the filtration of the samples
can be performed without loss of analyte.
5. Stability of Standard Solutions
Stability of standard and sample solutions was
determined by monitoring the solutions of standard (CGH 2SO 4) and of a tablet solution sample over a period of
two weeks (14). The results showed that the retention
times and signals were almost unchanged (RSD % <1.0)
and that no significant degradation was observed within
the given period, indicating the solutions were stable for
at least two weeks.
II. Potentiometric Method
Plasticized PVC membrane sensor incorporating
TpClPB-clopidogril ion pair was prepared with suit-

Table 3. Response characteristics of TpClPB-clopidogrel PVC
membrane sensor
Parameter
Slope, (mV decade-1)
Intercept, (mV)
Correlation coefficient, (r)
Lower limit of detection, (M)

Value
o-NPOE

DOP

61.7

59.3

218.5

201.4

0.9874

0.9993
-5

1.0 × 10-5

-5

1.0 × 10

Lower limit of linear range, (M)

5.0 × 10

4.0 × 10-5

Working pH range

1.5 - 4.0

1.5 - 4.0

Life span/week

11

12

able solvent mediators and electrochemically evaluated
as membrane sensor for clopidogrel under static mode
of operations according to IUPAC recommendations (18).
The membrane was prepared using a casting solution of
the composition 7:63:30 wt % of KTpClPB, o-nitrophenyl
octyl ether or dioctyl phthalate and PVC, respectively.
The two plasticizers have different dielectric constants.
The sensor was soaked in drug solution and tested as
clopidogrel sensor. Table 3 summarizes the potentiometric response characteristics of the sensor. It was found
that the clopidogrel sensor plasticized with the two different plasticizers have almost the same characteristics. The
sensor showed Nernstian response over the concentration
range of 1.0 × 10 -5 - 5.0 × 10 -2 mol L -1 clopidogrel with
cationic slopes of 61.7 and 59.3 mV decade -1 for o-NPOE
and DOP based sensor, respectively. The detection limit
was 1.0 × 10 -5 M with both plasticizers. Least squares
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(III) Determination of Clopidogrel

-250

E (mV)

-300

a: DOP
b: o-NPOE

Validity of the clopidogrel PVC membrane sensor
for the determination of clopidogrel was assessed by
determining 4.2 µg - 4.2 mg mL -1 standard clopidogrel
hydrogen sulphate using the calibration graph method.
The results obtained showed an average recovery of
100.65% and a mean standard deviation of 0.86% (n = 5)
using both solvent mediators based sensors. Clopidogrel
(as anticoagulants) in different pharmaceutical preparations was also determined (Table 5). Average recoveries
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a
b
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Figure 3. Potentiometric response of TpClPB – clopidogrel PVC
membrane sensor.

Table 4. Potentiometric selectivity coeff icients of TpClPBclopidogrel PVC membrane sensor

analysis of the data gave the relationships: E(mV) = 61.7
log(CG) - 218.5 and E(mV) = 59.3 log(CG) - 201.4 for oNPOE and DOP based sensor, respectively. A typical
calibration plot of the sensor is shown in Figure 4. The
sensor displayed constant and stable potential readings
within 0.2 mV from day to day and the calibration slope
did not change by more than 1.0 mV decade-1 over a
period of 11 weeks. The sensor was useful for 11 and 12
weeks for o-NPOE and DOP based sensor, respectively.
(I) Effect of pH

o-NPOE

DOP

Glucose

3.1 × 10-4

4.1 × 10-4

Maltose

2.3 × 10-4

3.4 × 10-4

Urea

2.5 × 10-3

1.1 × 10-2

Ba+2

2.6 × 10-3

7.7 × 10-3

Mg+2

2.1 × 10-3

6.9 × 10-3

Na+

2.6 × 10-3

6.9 × 10-3

NH4+

5.8 × 10-3

2.5 × 10-2

K+

9.0 × 10-4

6.4 × 10-3

Ca+2

1.2 × 10-3

4.8 × 10-3

Fe+2

9.3 × 10-3

3.3 × 10-2

-300

E (mV)

Influence of pH on the potentiometric response of the
sensor was studied using 10 -4, 10 -3 and 10 -2 M of clopidogrel solutions (Figure 4). From pH-potential profiles,
it is evident that the potential readings are constant over
the pH range 1.5 - 4.0. Within this acidic range, clopidogril is completely soluble, dissociated and sensed as a
monovalent charged ion. At pH values lower than 1.5, the
potential readings decreased due to interference by H+
ions. At higher pH values (>4.0), progressive precipitation of the drug was observed.

k pot
CG.,B

Interferent, B

(A)

-350

10-2M

-400

10-3M

-450
-500

(II) Effect of Foreign Ions

10-4M
1

2

3

4

5

pH
-300

(B)

-350

E (mV)

The potentiometric response of TpClPB-clopidogrel
PVC membrane sensor was tested in the presence of
several inorganic cations. Potentiometric selectivity
pot
coefficients k CG.,B were used to evaluate the degree of
interference. The data given in Table 4 were obtained using
the separate solutions method(16,18) at 10 -2 M clopidogrel.
It is clear that the sensor is highly selective for clopidogrel
ions compared with some common cations. Pharmaceutical excipients and diluents (e.g., glucose, maltose, manitol,
starch, talc powder and magnesium stearate) at concentration as high as 400-fold molar excess over clopidogril did
not interfere. The o-NPOE based sensor was generally
more selective than the DOP based sensor.

10-2M

-400
10-3M
-450
10-4M
-500

1

2

3

4

5

pH

Figure 4. pH – potential profile of TpClPB-clopidogrel PVC based
membrane sensor. (A) DOP and (B) o-NPOE.
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Table 5. Determination of clopidogrel in pharmaceutical preparations using TpClPB-clopidogrel PVC membrane sensor
Trade name and source

Nominal content (mg/tab)

Recovery* (%)
o-NPOE

DOP

100.8 ± 0.2

100.5 ± 0.2

Plavix
“Pharma Company,
6 October City, Cairo, Egypt”

75 mg / tab

*Average of 5 measurements.

of 100.8% and 100.5% of the nominal and mean standard
deviation of 0.84% and 0.89% for the o-NPOE and DOP
based sensors were obtained, respectively.

ConclusionS
From the present work we can conclude that there
are different advantages where the sensor technique
more simple and cheaper than HPLC techniques. On the
other hand, HPLC gave a rapid (less than 5 min) analysis, higher accuracy and precision, and lower LOD than
sensor method and because of the good accuracy, no
internal standard was needed. The methods can be used
for determination of (CG-H 2SO 4) in tablets without any
interferences.
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